Next Article in Journal
A Specific Oligodeoxynucleotide Promotes the Differentiation of Osteoblasts via ERK and p38 MAPK Pathways
Next Article in Special Issue
The Tricyclodecan-9-yl-xanthogenate D609 Triggers Ceramide Increase and Enhances FasL-Induced Caspase-Dependent and -Independent Cell Death in T Lymphocytes
Previous Article in Journal
Synthesis and Electrochemical Proprieties of Novel Unsymmetrical Bis-Tetrathiafulvalenes and Electrical Conductivity of Their Charge Transfer Complexes with Tetracyanoquinodimethane (TCNQ)
Previous Article in Special Issue
Apoptosis Signaling Is Altered in CD4+CD25+FoxP3+ T Regulatory Lymphocytes in Pre-Eclampsia
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2012, 13(7), 7886-7901;

Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer

Department of Systems Medicine, University of “Tor Vergata”, Via Montpellier 1, Rome 00133, Italy
Author to whom correspondence should be addressed.
Received: 1 June 2012 / Revised: 18 June 2012 / Accepted: 20 June 2012 / Published: 25 June 2012
(This article belongs to the Collection Programmed Cell Death and Apoptosis)
Full-Text   |   PDF [322 KB, uploaded 19 June 2014]


Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), a member of the TNF superfamily, interacts with its functional death receptors (DRs) and induces apoptosis in a wide range of cancer cell types. Therefore, TRAIL has been considered as an attractive agent for cancer therapy. However, many cancers are resistant to TRAIL-based therapies mainly due to the reduced expression of DRs and/or up-regulation of TRAIL pathway-related anti-apoptotic proteins. Compounds that revert such defects restore the sensitivity of cancer cells to TRAIL, suggesting that combined therapies could help manage neoplastic patients. In this article, we will focus on the TRAIL-sensitizing effects of natural products and synthetic compounds in colorectal cancer (CRC) cells and discuss the molecular mechanisms by which such agents enhance the response of CRC cells to TRAIL. View Full-Text
Keywords: DR4; DR5; caspase-8; p53; CHOP; survivin; extrinsic pathway; intrinsic pathway; chemotherapeutics; natural products DR4; DR5; caspase-8; p53; CHOP; survivin; extrinsic pathway; intrinsic pathway; chemotherapeutics; natural products
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Stolfi, C.; Pallone, F.; Monteleone, G. Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer. Int. J. Mol. Sci. 2012, 13, 7886-7901.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top